Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience aspergillosis infection and they may start using isavucona...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2023-05-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1168852/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|